JNJ-4804 Doubles Remission in Refractory Crohn's

Johnson & Johnson (NYSE: JNJ) reported Phase IIb data showing that JNJ-4804 (also known as JNJ-78934804), its investigational co-antibody combining guselkumab and golimumab, produced clinical remission rates roughly double those of golimumab monotherapy at Week 48 in patients with refractory Crohn's disease. There were also comparable directional advantages in ulcerative colitis, prompting the company to announce plans for two Phase III trials.

Dual-pathway blockade in refractory IBD

The DUET-CD and DUET-UC studies are randomized, double-blind, dose-ranging Phase IIb trials comparing JNJ-4804 against placebo and active comparators — golimumab and Tremfya (guselkumab) — in adults with moderately to severely active Crohn's disease or ulcerative colitis who had inadequate response or intolerance to one or more systemic therapy classes. Approximately half of participants in each study had failed two or more therapy classes, forming a highly treatment-experienced subpopulation.

The rationale for the JNJ-4804 inflammatory bowel disease program rests on the observation that IBD involves at least two non-redundant inflammatory axes. TNF-α drives acute mucosal inflammation and is the target of the most widely used biologic class in IBD, while IL-23 governs downstream Th17-mediated chronic inflammation. Blocking one pathway while the other remains active may explain the loss of response that is common with monotherapy over time. JNJ-4804 delivers a fixed-dose combination of guselkumab and golimumab in a single subcutaneous injection, aiming to achieve simultaneous pathway suppression without requiring separate dosing of two agents.

Phase IIb Results: Crohn's Disease

In DUET-CD, the co-primary endpoints were clinical remission and endoscopic response at Week 48. In the overall population, the JNJ-4804 high-dose group achieved clinical remission in 50.8% of patients, compared with 25.4% for golimumab and 42.5% for guselkumab. Endoscopic response rates followed a similar pattern: 38.1% for JNJ-4804 versus 19.8% for golimumab and 33.9% for guselkumab.

The Crohn's disease clinical trial results were more pronounced in the highly refractory subgroup — those who had failed two or more therapy classes. In that population, the company said clinical remission rates for JNJ-4804 were nearly double the highest comparator rate, and endoscopic response was more than 60% higher than the next best arm. Absolute figures for that subgroup were not disclosed in the press release.

Golimumab vs JNJ-4804: The Comparator Gap

The gap between golimumab and JNJ-4804 in DUET-CD is the most interpretable signal from the Crohn's data. Golimumab is an established TNF inhibitor approved in other inflammatory conditions, and its performance in this trial provides a direct benchmark for the incremental contribution of the IL-23 component. The roughly 25-percentage-point difference in clinical remission between JNJ-4804 and golimumab in the overall CD population is directionally consistent with the hypothesis that dual-pathway blockade adds meaningful efficacy in patients where TNF inhibition alone is insufficient. However, cross-trial comparisons are limited, and the magnitude of the comparator gap in a Phase IIb dose-ranging study should be interpreted cautiously ahead of adequately powered Phase III data.

Phase IIb Results: Ulcerative Colitis

In DUET-UC, the primary endpoint was clinical remission at Week 48, defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 per central review. JNJ-4804 ulcerative colitis remission rates reached 41.0% in the overall population, compared with 11.5% for golimumab and 34.0% for guselkumab. The gap between JNJ-4804 and golimumab here is notably wider than in CD — nearly 30 percentage points — though the golimumab arm's 11.5% rate in a treatment-experienced UC population is low relative to its known performance in biologic-naive patients, which may reflect the refractory nature of the enrolled population.

Key secondary endpoints included corticosteroid-free clinical remission, endoscopic improvement, and histologic remission with endoscopic improvement. The press release did not provide numerical results for these endpoints, noting only that JNJ-4804 showed improvements across multiple clinical and endoscopic measures. In the highly refractory UC subgroup, the clinical remission rate for JNJ-4804 was described as almost 60% higher than the closest comparator.

Safety findings across both studies were described as consistent with the known profiles of the component monotherapies. No new safety signals were identified, though detailed adverse event tables were not released.

Where JNJ-4804 sits in a crowded landscape

The refractory IBD treatment landscape has expanded considerably over the past decade, with approved options now spanning TNF inhibitors, IL-12/23 inhibitors, IL-23 p19 inhibitors, integrin inhibitors, and JAK inhibitors. Despite this, a meaningful proportion of patients either fail to respond to initial therapy or lose response over time, cycling through successive monotherapies with diminishing returns. The DUET program targets that population directly, enrolling patients who had already failed at least one systemic therapy class.

The Johnson & Johnson antibody therapy approach differs from combination regimens that are administered as separate agents — such as the investigational use of vedolizumab plus an anti-TNF — by delivering both components in a single fixed-dose subcutaneous injection. Whether that formulation advantage translates into clinical or commercial differentiation will depend partly on the Phase III data and partly on how payers and prescribers weigh the convenience factor against the cost of a novel bispecific-adjacent molecule.

Guselkumab, one of JNJ-4804's components, already holds FDA approval for moderately to severely active UC and CD under the Tremfya brand, which means the IL-23 contribution to JNJ-4804's efficacy is not entirely novel. The question the Phase III program will need to answer is whether the fixed combination consistently outperforms guselkumab monotherapy in a registrational-grade trial, particularly given that guselkumab's own Phase IIb arm in DUET showed remission rates of 34.0% in UC and 42.5% in CD — both numerically lower than JNJ-4804 but not by margins that are yet statistically characterized in the available data.

Johnson & Johnson said it will initiate the Phase III DUET ENCORE-CD trial in adults with moderately to severely active Crohn's disease and the Phase III DUET ENCORE-UC trial in adults with moderately to severely active ulcerative colitis, with the Phase IIb DUET data serving as the basis for advancing to registration-enabling studies.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article